Enhancement of the antitumor effect by the concurrent use of a monoclonal antibody and the protein-bound polysaccharide PSK in mice bearing a human cancer cell line. 1994

T Kanoh, and K Saito, and K Matsunaga, and Y Oguchi, and N Taniguchi, and H Endoh, and M Yoshimura, and T Fujii, and C Yoshikumi
Kureha Chemical Ind. Co., Ltd., Biomedical Research Laboratories, Tokyo, Japan.

The antitumor effects of a monoclonal antibody against a human cancer cell line and a protein-bound polysaccharide, PSK, obtained from cultured mycelia of Coriolus versicolor in basidiomycetes were examined. The IgG2a monoclonal antibody against the human colon cancer cell line colo 205 induced in vitro antibody-dependent macrophage-mediated cytotoxicity against the cancer cells, but only slightly suppressed the in vivo growth of the cancer cells. Concurrent use of PSK with the antibody enhanced the in vitro antibody-dependent macrophage-mediated cytotoxicity as well as the in vivo antitumor activity. These findings suggest that the combined use of a monoclonal antibody and PSK, which have different modes of action, may be useful in the treatment of cancer.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D011509 Proteoglycans Glycoproteins which have a very high polysaccharide content. Proteoglycan,Proteoglycan Type H
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic

Related Publications

T Kanoh, and K Saito, and K Matsunaga, and Y Oguchi, and N Taniguchi, and H Endoh, and M Yoshimura, and T Fujii, and C Yoshikumi
January 1979, Advances in experimental medicine and biology,
T Kanoh, and K Saito, and K Matsunaga, and Y Oguchi, and N Taniguchi, and H Endoh, and M Yoshimura, and T Fujii, and C Yoshikumi
September 1987, Journal of clinical & laboratory immunology,
T Kanoh, and K Saito, and K Matsunaga, and Y Oguchi, and N Taniguchi, and H Endoh, and M Yoshimura, and T Fujii, and C Yoshikumi
January 1999, International journal of clinical & laboratory research,
T Kanoh, and K Saito, and K Matsunaga, and Y Oguchi, and N Taniguchi, and H Endoh, and M Yoshimura, and T Fujii, and C Yoshikumi
May 1989, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
T Kanoh, and K Saito, and K Matsunaga, and Y Oguchi, and N Taniguchi, and H Endoh, and M Yoshimura, and T Fujii, and C Yoshikumi
January 1988, International journal of immunopharmacology,
T Kanoh, and K Saito, and K Matsunaga, and Y Oguchi, and N Taniguchi, and H Endoh, and M Yoshimura, and T Fujii, and C Yoshikumi
August 2007, Cellular & molecular immunology,
T Kanoh, and K Saito, and K Matsunaga, and Y Oguchi, and N Taniguchi, and H Endoh, and M Yoshimura, and T Fujii, and C Yoshikumi
January 1985, Biochemical and biophysical research communications,
T Kanoh, and K Saito, and K Matsunaga, and Y Oguchi, and N Taniguchi, and H Endoh, and M Yoshimura, and T Fujii, and C Yoshikumi
July 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
T Kanoh, and K Saito, and K Matsunaga, and Y Oguchi, and N Taniguchi, and H Endoh, and M Yoshimura, and T Fujii, and C Yoshikumi
January 1988, International journal of immunopharmacology,
T Kanoh, and K Saito, and K Matsunaga, and Y Oguchi, and N Taniguchi, and H Endoh, and M Yoshimura, and T Fujii, and C Yoshikumi
January 1988, The Journal of international medical research,
Copied contents to your clipboard!